Abstract
Extracellular vesicles, in particular the subclass exosomes, are rapidly emerging as a novel therapeutic platform. However, currently very few clinical validation studies and no clearly defined manufacturing process exist. As exosomes progress towards the clinic for treatment of a vast array of diseases, it is important to define the engineering basis for their manufacture early in the development cycle to ensure they can be produced cost-effectively at the appropriate scale. We hypothesize that transitioning to defined manufacturing platforms will increase consistency of the exosome product and improve their clinical advancement as a new therapeutic tool. We present manufacturing technologies and strategies that are being implemented and consider their application for the transition from bench-scale to clinical production of exosomes.
| Original language | English |
|---|---|
| Pages (from-to) | 242-256 |
| Number of pages | 15 |
| Journal | Trends in Molecular Medicine |
| Volume | 24 |
| Issue number | 3 |
| Early online date | 12 Feb 2018 |
| DOIs | |
| Publication status | Published - Mar 2018 |
Bibliographical note
© 2018, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 InternationalFunding: Ministry of Education, Science and Technology (grant No. 2009-0093829). Engineering and Physical Science Research Council (EPSRC) Industrial Doctoral Training Centre in Bioprocess Engineering Leadership (EP/G034656/1).
Keywords
- exosomes;
- regenerative medicine
- process development
- commercial manufacturing